DOCSLIB.ORG

Pha Pharm • I Teaching Expe Series of Participations • I Am Workin Experience • I Am Pharmaceutica of New Pharm

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pha Pharm • I Teaching Expe Series of Participations • I Am Workin Experience • I Am Pharmaceutica of New Pharm E U R O P E A N CURRICULUM VITAE F O R M A T SCIENTIFIC CURRICULUM VITAE PERSONAL INFORMATION Name DR. PIPERAKI , Stavroula-Ina Address in Athens 20, ANDREA PAPANDREOU STR ., GR - 15127, MELISSIA , ATHENS , GREECE Address in Paris 10, AVENUE ALPHAND , 75116, PARIS , FRANC E Telephone GSM +30 6944 320903, +30 210 8047689, +33(0)965297780 FRANCE , E-mail [email protected] , [email protected] , Nationality Hellenic SUMMARY / PROFILE • Pha rmacist, PhD Degree , and a great experience in research, pharm aceutical industry, business and computer sci ences. • I am working for many years on academic research and I have a great teaching experience at University level. The outcome of this work is a se ries of 19 publications in international journals as we ll as 23 participations in international symposia and many lectures . • I am working as an International B usiness Consultant (see “work experience ” section ). • I am successfully involved in the worldwid e development of new pharmaceutical compounds and the pre- and pos t-marketing surveillance of new pharmaceutical entities , as well as Pricing and Reimbursement strategies , in a multinational pharmaceutical company (Sanofi S.A.) directing the Regulatory Aff airs and Pharmacovigilance Departments. • I establish ed my one company , a private business . Further, I have created a computer assisted Pharmaceutical Care Centered . This work gave me the opportunity to have a direct interaction with the public and to handl e, on a first -degree, health care issues related to drug safety, efficacy, as well as drug monitoring and Pharmacovigilance reporting . • BEPA ( Bureau of European Policy Adviser s) of the European Commission : Representative of a NPO within the BEPA (active p articipation on meetings, making presentations, lobbing and presidency of think -tank European group). • In my career I have been always characterized by excellent interpersonal skills coupled with a proactive and entrepreneurial approach and thus, I can c ommunicate to the public and build good working relationships. Based on my experience, I am capable of providing leadership for timetabling, strategic objectives, budget building and analysis, coordinating activities carried out through group; further, wor king with good project management flair, I can ensure that developmental timetables and objectives can be met. • I have excellent knowledge of French and English, as well as good knowledge of Portuguese and elementary of Italian . • Exc ellent knowledge of Computer P rogramming, Social Networking, as well as excellent knowledge of MS Office (word, excel, powerpoint, etc.) • Honors: awards & distinctions , listed in international biographical dictionaries, university & nationa l school awards for “Excellency” . CORE COMPETENCIES Business & pharmaceutical industry, pharmaceutical science & research, pharmaceutical development, regulatory affairs, pharmacovigilance, personalized medicine , pharmaceutical care, sales, computer programming , foreign languages. Page 1 - Curriculum vitae of Dr.r. PPIPERAKI, Stavroula-Ina WORK EXPERIENCE Type of business or sector Pharmaceutical Sciences - Private Sector July 1997 – now INTERNATIONAL CONSULTANT @ OWNER OF A PRIVATE BUSINESS • International Consultant : Business Consultancy ∴ Strategic Planning ∴ Research & Development ∴ Regulatory Affairs & Pharmacovigilance ∴ Market Research & Feasibility Studies ∴ Crisis Management ∴ Lobbying ∴ Social Networks Management ∴ Quality and Knowledge Management ∴ Business Process Re-engineering ∴ Cluster Management ∴ Innovation & Creativity. • Creation & Management of a private business • Establishment of A PHARMACEUTICAL CARE CENTER supported by a Computer Assisted Program of Pharmaceutical Care and Pharmacovigilance Reporting. & Type of business or sector Private Sector 2009 - now BEPA ( Bureau of European Policy Advisers ) of the European Commission: Representative of a NPO within the BEPA. & Type of business or sector Pharmaceutical Sciences July 1997 – now SCIENTIFIC ASSOCIATE IN THE UNIVERSITY OF ATHENS , in the topics of Pharmaceutical Chemistry, Personalized Medicine & Pharmaceutical Care, May 1993 -June 1998 DIRECTOR REGULATORY AFFAIRS & PHARMACOVIGILANCE , R&D DEPARTMENTS Sanofi S.A. Type of business or sector Pharmaceutical Industry • Directing the teams of the two departments and successfully accomplishing the following responsibilities related to my job profile: • Representing the Affiliate in the Corporate R &D Department , participating in the European and the International Decision Development Team concerning the company’s new products portfolio; • Quality Assurance Manager & “Pharmacien Responsable ”, for the local production plant; • Representing the company within the European Medicines Agency , related to procedures of drug marketing authorization licenses as well as Pricing and Reimbursement strategies; • Working in collaboration with the EME for the approval to conduct Clinical Trials in hospitals as well as pre-and post-marketing Pharmacovigilance procedures and reports (EudraVigilance ); • Representing the company within the National Organization for Medicines; • Representing the affiliate within the “ United Cities & Local Governments Organisms”, concerning environmental safety issues related to chemical entities and residues; • Representing the company in the National Organism of Industrial and Intellectual Properties and within the Corporate International Trademarks Department ; • Directing the Regulatory Affairs & Pharmacovigilance activities in other countries in Europe. January 1997- December 1994 1. TEACHING ON THE POSTGRADUATE PROGRAM OF “PHARMACEUTICAL ANALYSIS ” Division of the Pharmaceutical Chemistry, University of Athens. Type of business or sector Pharmaceutical Sciences General subject: “Advanced Courses on Pharmaceutical Analysis”, covering the following topics: • “Chiral Chromatography in drug analysis: Theory” • “Chiral Chromatography in drug analysis”(Laboratory lesson) • “Capillary Electrophoresis: theory and principles” • “Capillary Electrophoresis: applications in the separation of chiral drugs” 2. TEACHING ON THE POSTGRADUATE PROGRAM OF “PHARMACEUTICAL TECHNOLOGY ”, Division of the Pharmaceutical Technology, University of Athens. Type of business or sector Pharmaceutical Sciences General subject: “Modern techniques in pharmaceutical analysis”. Page 2 - Curriculum vitae of Dr. PIPERAKI, Stavroula-Ina WORK EXPERIENCE January 1994–August 1994 COLLABORATION WITH THE UNIVERSITY OF YORK Type of business or sector Pharmaceutical Sciences Invited by the Professor Dr. David Goodall ( University of York – Department of Chemistry ) to visit his research group and initiate a collaboration study, in both Liquid Chromatography and Capillary Electrophoresis in order to produce a unified theory on chiral separations. The result of this successful and innovative project was a joint research paper, presented to the 3rd International Symposium on Capillary Electrophoresis, and a scientific publication in the Journal of Chromatography. This research program was sponsored by the British Council of Athens after the submission and the approval of a relevant project. September 1991–April 1993 TWO YEAR RESEARCH PROGRAM Type of business or sector Pharmaceutical Sciences Participation in a two-year research program supported by the National Drug Organization for the subsidy of a doctoral thesis. January 1991 – June 1992 SCIENTIFIC TRAINING MANAGER – PART TIME JOB , Pancosmetic Hellas Ldt Type of business or sector Pharmaceutical Industry Organisational structuring of a Training Department: Setting up a scientific library; Creation of relevant bibliography and its monitoring; Setting up two series of lectures for the Training of Executives on scientific topics in the field of Cosmetology (see Lectures ‘section). January 1990–September 1993 POSTGRADUATE SCHOLAR Type of business or sector Pharmaceutical Sciences Division of Pharmaceutical Chemistry, Laboratory of Pharmaceutical Analysis. Teaching in the “Laboratory Lessons of Pharmaceutical Analysis”. SCIENTIFIC PUBLICATIONS Type of sector Scientific Research – Pharmaceutical Sciences Scientific Research – Pharmaceutical S. Piperaki Pharmaceutiki Sciences 1. , , 25, 2013. “Academic Education and Life Long Learning: Horizon 2020 & the evolution of the pharmaceutical profession in Europe”. 2. S. Piperaki , Pharmaceutiki , 24, 2012. “The Age of Personalized Medicine : pharmacogenomics, the development of a targeted therapy”. 3. S. Piperaki , PHARMACY Management & Communication , 11 , July 2011. ‘’Pharmaceutical Care Services in a post-crisis business environment’’. 4. Branimir Bertoša, Biserka Kojić-Prodić, Rebecca C. Wade, , Michael Ramek, Stavroula Piperaki , Anna Tsantili-Kakoulidou, and Sanja Tomić, J. Chem. Inf. Comput. Sci., 43(5) , 1532-1541, July 2003. “A new approach to predict the biological activity of molecules based on similarity of their interaction fields and the logP and logD values: application to auxins”. 5. A.Tzantili-Kakoulidou, I. Panteri, S. Piperaki , F. Csizmadia and F. Darvas, European J. Drug Metab. & Pharmacokinetics , 24(3), 205-212, 2000. “Prediction of distribution coefficients from structure comparison of calculated and experimental data for various drugs”. 6. V. Lambroussi , S. Piperaki , A. Tzantili-Kakoulidou, J. of Planar Chromatogr ., 12 , 124-128, 1999. “Formation of inclusion complexes between cyclodextrins as mobile phase additives in RPTLC, and Fluoxetine, Norfluoxetine and Promethazine”. 7. A.Tzantili-Kakoulidou, S.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0081713 A1 Sharma Et Al
    US 20100081713A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0081713 A1 Sharma et al. (43) Pub. Date: Apr. 1, 2010 (54) COMPOSITIONS AND METHODS FOR (22) Filed: Mar. 18, 2009 TREATINGVIRAL INFECTIONS Related U.S. Application Data (75) Inventors: Geeta Sharma, Singapore (SG); (60) Provisional application No. 61/069,917, filed on Mar. Ralf Altmeyer, Singapore (SG); 19, 2008. Vishal Pendharker, Singapore (SG); Yu Chen, Singapore (SG); Publication Classification Michael Foley, Chestnut Hill, MA (51) Int. Cl. (US) A63L/35 (2006.01) A6II 3L/25 (2006.01) Correspondence Address: A63L/35 (2006.01) Gearhart Law LLC A6II 3/13 (2006.01) 4 Femdale Avenue A6IP3L/2 (2006.01) Chatham, NJ 07928 (US) (52) U.S. Cl. .......... 514/459; 514/529; 514/647: 514/662 (73) Assignee: CombinatoRx, (Singapore) Pte. (57) ABSTRACT Ltd. The present invention provides compositions, methods, and kits for treating or preventing a viral infection (e.g., an infec (21) Appl. No.: 12/406,716 tion caused by an influenza virus). Patent Application Publication Apr. 1, 2010 Sheet 1 of 2 US 2010/0081713 A1 ------ 80 r -0. Vehicle 0.5% HPMC g - - Sertraline-30mg/kg/day - £ 60 “A Sertraline-100mg/kg/day/kg/day i -v. Oseltamivir-30mg/kg/day ...i -0. Oseltamivir-100mg/kg/day -0. (Sertraline 30mg/kg+ . 40 Prednisolone 0.1 mg/Kg) Figure 1 Patent Application Publication Apr. 1, 2010 Sheet 2 of 2 US 2010/0081713 A1 100 468OOO 2 O Wehicle Sentraline 10 mg/kg Sentraline 30mg/kg Setraline 100mg/kg Figure 2 US 2010/008 1713 A1 Apr.
    [Show full text]
  • Pharmacopoeial Reference Standards and Their Current Lot Numbers EP, EPISA, ICRS, BP July 2019
    Pharmacopoeial reference standards and their current lot numbers EP, EPISA, ICRS, BP July 2019 Mikromol Follow LGC on LinkedIn Dear user, This catalogue includes all pharmacopoeial reference materials from EP, EPISA, ICRS and BP available at LGC, as well as their current lot numbers. We update the catalogue on a monthly basis so that you can use the lot numbers to easily track the expiry dates of your stocked reference materials. We took the lot information from actual data from pharmacopoeias, correct at the time of production. We retained all spelling and information as provided by the pharmacopoeias. The list was compiled with caution, however, errors in this list may be possible, and LGC is not responsible for any consequences as a result of these errors, may it be errors in the original Pharmacopoeial data, or from LGC during compilation of this list. For any questions or orders please contact your local LGC office. You will find all contact details on the last page of this list. Alternatively, you can browse and buy pharmaceutical reference materials online at lgcstandards.com/mikromol. Stay connected via LinkedIn (LGC Mikromol) or Twitter @LGCMikromol. Kind regards Your LGC Standards Team LGC, Queens Road, Teddington, Middlesex, TW11 0LY, United Kingdom Tel: +44 (0)20 8943 8480 Fax: +44 (0)20 8943 7554 E-mail: [email protected] European Pharmacopoeia (EP) Available Current Unit Cat. No. Name What is new? since Batch No. Quantity EPY0001552 Abacavir for peak identification 1 10 mg EPY0001551 Abacavir for system suitability 1
    [Show full text]
  • Departamento De Química - Física
    DEPARTAMENTO DE QUÍMICA - FÍSICA SELECCIÓN DE NUEVOS ANTIBACTERIANOS POR TOPOLOGÍA MOLECULAR VICTORIA EUGENIA SIMÓN GARCÍA UNIVERSITAT DE VALENCIA Servei de Publicacions 2004 Aquesta Tesi Doctoral va ser presentada a Valencia el día 04 de Desembre de 2003 davant un tribunal format per: - D. José Luis Moreno Frigols - Dª. Mª Teresa Salabert Salvador - D. Enrique Hernández Jiménez - Dª. Stella Moreno Grau - Dª. Marina Herraez Domínguez Va ser dirigida per: D. Facundo Pérez Giménez D. Francisco José García March ©Copyright: Servei de Publicacions Victoria Eugenia Simón García Depòsit legal: I.S.B.N.:84-370-5170-3 Edita: Universitat de València Servei de Publicacions C/ Artes Gráficas, 13 bajo 46010 València Spain Telèfon: 963864115 UNIVERSITAT DE VALÈNCIA FACULTAT DE FARMÀCIA DEPARTAMENT DE QUÍMICA FÍSICA "SELECCIÓN DE NUEVOS ANTIBACTERIANOS POR TOPOLOGÍA MOLECULAR" Memoria para optar al Grado de Doctora en Farmacia, presentada por: VICTORIA EUGENIA SIMÓN GARCÍA Directores: Prof. Dr. D. FACUNDO PÉREZ GIMÉNEZ Prof. Dr. D. FRANCISCO JOSÉ GARCÍA MARCH 1 2 DPTO. QUÍMICA FÍSICA FACULTAD DE FARMACIA Av. Vicente Andrés Estellés s/n Tf. 963 86 48 94 Fax 963 86 48 92 46100 BURJASSOT (Valencia) ESPAÑA D. FACUNDO PÉREZ GIMÉNEZ y D. FRANCISCO JOSÉ GARCÍA MARCH, Doctores en Farmacia y Profesores Titular y Asociado del Departamento de Química Física de la Facultad de Farmacia de la Universidad de Valencia, CERTIFICAN: Que la Tesis Doctoral presentada sobre el tema “Selección de nuevos antibacterianos por topología molecular” ha sido realizada bajo nuestra dirección por la Licenciada en Farmacia Dña. VICTORIA EUGENIA SIMÓN GARCÍA y mediante este escrito, autorizan su presentación para optar al grado de Doctora en Farmacia.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8.242,110 B2 Deregnaucourt Et Al
    USOO824211 OB2 (12) United States Patent (10) Patent No.: US 8.242,110 B2 Deregnaucourt et al. (45) Date of Patent: Aug. 14, 2012 (54) USE OF ANTIHISTAMINEAGENTS FOR THE FOREIGN PATENT DOCUMENTS PREVENTIVE OR EARLY TREATMENT OF FR 2802 101 A1 6, 2001 INFLAMMATORY SYNDROMES, IN JP 4-89428 A 3, 1992 PARTICULAR THOSE TRIGGERED BY JP 2001-151677 A 6, 2001 TOGAVIRUSES WO WO-96,04787 A1 2, 1996 (75) Inventors: Jean Deregnaucourt, Paris (FR): OTHER PUBLICATIONS Etienne Andre, Seyssinet-Pariset (FR): Wilson, Annals of Rheumatic Diseases, 1953; 12(1):38-39.* Jacky Tisne-Versailles, Castres (FR) Storms, Journal of Allergy and Clinical Immunology, 2004; 114:S146-153.* (73) Assignee: Pierre Fabre Medicament, Satake et al., Journal of Cardiovascular Pharmacology, Boulogne-Billancourt (FR) 1994:23(4):669-673 (abstract only).* Toovey et al., Travel Medicine and Infectious Disease, vol.2, No. 3-4, (*) Notice: Subject to any disclaimer, the term of this 2004, pp. 189-191. patent is extended or adjusted under 35 Suhrbier et al., Current Opinion in Rheumatology, vol. 16, No. 4. U.S.C. 154(b) by 809 days. 2004, pp. 374-379. Stocks et al., Australian Family Physician, vol. 26, No. 6, Jun. 1997. (21) Appl. No.: 12/224,830 pp. 710-717. Paganin et al., Presse Medicale 2006, vol. 35. No. 4 II, 2006, pp. (22) PCT Filed: Mar. 9, 2007 641-646. Ware et al., Medical Care, vol. 34, No. 3, 1996, pp. 220-233. (86). PCT No.: PCT/EP2007/052237 Bruce et al., The Journal of Rheumatology, vol. 30, No. 1, 2003, pp.
    [Show full text]
  • 2 12/ 35 74Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 March 2012 (22.03.2012) 2 12/ 35 74 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/16 (2006.01) A61K 9/51 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/14 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/065959 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 14 September 201 1 (14.09.201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/382,653 14 September 2010 (14.09.2010) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, NANOLOGICA AB [SE/SE]; P.O Box 8182, S-104 20 ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, Stockholm (SE).
    [Show full text]
  • Ep 2301628 A1
    (19) & (11) EP 2 301 628 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 30.03.2011 Bulletin 2011/13 A61P 37/06 (2006.01) (21) Application number: 10013062.4 (22) Date of filing: 13.10.2004 (84) Designated Contracting States: • Manivasakam, Palaniyandi AT BE BG CH CY CZ DE DK EE ES FI FR GB GR West Roxbury HU IE IT LI LU MC NL PL PT RO SE SI SK TR MA 02132 (US) Designated Extension States: • Hurst, Nicole AL HR LT LV MK Boston MA 02132 (US) (30) Priority: 15.10.2003 US 512415 P • Foley, Michael A. Chestnut Hill (62) Document number(s) of the earlier application(s) in MA (US) accordance with Art. 76 EPC: • Slavonic, Michael S. 09002049.6 / 2 070 550 Quincy 04809944.4 / 1 680 121 MA 02169 (US) • Smith, Brendan (71) Applicant: Zalicus Inc. Sommerville Cambridge, MA 02142 (US) MA 02118 (US) • Auspitz, Benjamin A. (72) Inventors: Cambridge • Keith, Curtis MA 02139 (US) Boston MA 02118 (US) (74) Representative: Bösl, Raphael Konrad • Borisy, Alexis Isenbruck Bösl Hörschler LLP Arlington Patentanwälte MA 02476 (US) Prinzregentenstrasse 68 • Zimmermann, Grant R. 81675 München (DE) Winchester MA 01890 (US) Remarks: •Jost-Price, Edward Roydon This application was filed on 01-20-2010 as a West Roxbury divisional application to the application mentioned MA 02132 (US) under INID code 62. (54) Methods and reagents for the treatment of immunoinflammatory disorders (57) The invention features, among others, a tetra- stituted pyrimidopyrimidine and a corticosteroid for use substituted pyrimidopyrimidine and a corticosteroid for ina method for treating an immunoinflammatory disorder.
    [Show full text]
  • Council of Europe Committee of Ministers (Partial
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies and superseding Resolution AP (77) 1) AND APPENDIX containing the list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 31 October 1982 RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION 1 (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands, the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969 and 5 May 1964, respectively, Considering that, under the terms of its Statute, the aim of the Council of Europe is to achieve a greater unity between its Members for the purpose of safeguarding and realising the ideals and principles which are their common heritage and facilitating their economic and social progress; Having regard to the
    [Show full text]
  • Mebhydrolin Napadisylate
    www.chemicalland21.com MEBHYDROLIN NAPADISYLATE SYNONYMS Diazolin; Diazoline; Mebhydroline 1,5-naphthalenedisulfonate salt; Diazolinum; Omeril; 5-Benzyl-1,3,4,5- tetrahydro-2-methyl-2H-pyrido(4,3-b)indole 1,5-naphthalenedisulfonate; 9-Benzyl-N-methyl-1,2,3,4- tetrahydro-alpha-carboline; Incidal; Mebhydroline napadisylate; PRODUCT IDENTIFICATION CAS RN 6153-33-9; 524-81-2 (Parent) EINECS RN 228-170-3 FORMULA (C19H20N2)2·C10H8O6S2 MOL WEIGHT 841.05 PHYSICAL AND CHEMICAL PROPERTIES PHYSICAL STATE white to almost white crystalline powder MELTING POINT 280 C (Decomposes) BOILING POINT DENSITY SOLUBILITY IN WATER pH VAPOR DENSITY REFRACTIVE INDEX FLASH POINT GENERAL DESCRIPTION Histamine H1-receptor antagonists are used to relieve the symptoms of an immediate allergic reaction. They have additional anti-inflammatory effects that could result from an inhibition of the transcription factors activator protein-1 (AP-1) and nuclear factor-kappa B (NF-kappaB). The implication of the H1- receptor in these effects is controversial. Diphenhydramine is a first-generation H1-receptor antagonist while mizolastine and desloratadine are second-generation compounds. Mizolastine is also an inhibitor of 5-lipoxygenase (5-LO), an enzyme that has been involved in NF-kappaB activation. (source: http://www.ingentaconnect.com) Antihistamines are medicines used to stop the effects of a substance in the blood called histamine. Histamine is a natural chemical produced by the immune (disease-fighting) system of the body. When it is released, it increases blood flow to the affected area. Liquid leaks out of the blood vessels, causing the mucous membranes lining the nose and throat to swell, and stimulating the nearby gland to produce mucus.
    [Show full text]
  • Use of Combinations Comprising a Corticosteroid and a Pyrimidopyrimidine in the Treatment of Inflammatory Diseases
    (19) & (11) EP 2 070 550 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 17.06.2009 Bulletin 2009/25 A61K 45/06 (2006.01) A61K 31/519 (2006.01) A61P 37/00 (2006.01) (21) Application number: 09002049.6 (22) Date of filing: 13.10.2004 (84) Designated Contracting States: • Borisy, Alexis AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Arlington, MA 02476 (US) HU IE IT LI LU MC NL PL PT RO SE SI SK TR • Zimmermann, Grant R. Designated Extension States: Somerville, MA 02144 (US) AL HR LT LV MK •Jost-Price, Edward Roydon West Roxbury, MA, 02132 (US) (30) Priority: 15.10.2003 US 512415 P • Manivasakam, Palaniyandi West Roxbury, MA 02132 (US) (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: (74) Representative: Bösl, Raphael Konrad 04809944.4 / 1 680 121 Isenbruck Bösl Hörschler Wichmann Huhn LLP Patentanwälte (71) Applicant: Combinatorx, Incorporated Prinzregentenstrasse 68 Cambridge, MA 02142 (US) 81675 München (DE) (72) Inventors: Remarks: • Keith, Curtis This application was filed on 13-02-2009 as a Boston, MA 02118 (US) divisional application to the application mentioned under INID code 62. (54) Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases (57) The invention features a method for treating a The invention also features a composition containing a patient diagnosed with, or at risk of developing, an im- tetra-substituted pyrimidopyrimidine in combination with munoinflammatory disorder by administering to the pa- one or more additional agents.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0130711 A1 LEDERMAN Et Al
    US 2011 013 0711A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0130711 A1 LEDERMAN et al. (43) Pub. Date: Jun. 2, 2011 (54) HAIR GROWTH TREATMENT Publication Classification (51) Int. Cl. (75) Inventors: Seth M. LEDERMAN, New York, A6M 37/00 (2006.01) NY (US); Scott C. KELLOGG, A6B 7/3209 (2006.01) Mattapoisett, MA (US); Shikha P. A6B 18/20 (2006.01) BARMAN, Bedford, MA (US) (52) U.S. Cl. ................................ 604/22: 606/167; 606/9 (57) ABSTRACT (73) Assignee: FOLLICA, INC., WALTHAM, The present disclosure provides methods and systems for MA (US) increasinghair growth in Subjects in need thereofdue to male or female-pattern hair loss, pathological hair loss, or hair loss after injury. By any use of any appropriate mechanical, elec (21) Appl. No.: 12/950,042 tromagnetic, or chemical means, the present disclosure per tains to the segmentation of hair follicles into two or more (22) Filed: Nov. 19, 2010 disunited subunits in order to form new follicles from the e - 19 respective Subunits. In contrast with known techniques for bisecting hair follicles and as described more fully herein, the Related U.S. Application Data present methods and systems permit the bisection of single follicles or populations of follicles with a high degree of (60) Provisional application No. 61/262,840, filed on Nov. efficiency, and thereby represent an effective treatment option 19, 2009. for those in need of increased hair growth. Patent Application Publication Jun. 2, 2011 Sheet 1 of 6 US 2011/O130711 A1 Patent Application Publication Jun. 2, 2011 Sheet 2 of 6 US 2011/O130711 A1 FIG 3 (a) (b) (c) (d) FIG.
    [Show full text]
  • Pharmacopoeial Reference Standards and Their Current Lot Numbers EP, EPISA, ICRS, USP, BP January 2017
    Pharmacopoeial reference standards and their current lot numbers EP, EPISA, ICRS, USP, BP January 2017 Follow LGC Standards Pharma on LinkedIn Dear user, This catalogue includes all pharmacopoeial reference materials from EP, EPISA, ICRS, USP and BP available at LGC, as well as their current lot numbers. We update the catalogue on a monthly basis so that you can use the lot numbers to easily track the expiry dates of your stocked reference materials. We took the lot information from actual data from the Pharmacopoeias and correct at the time of production. We retained all spelling and information as provided by the Pharmacopoeias. The list was compiled with caution, however errors in this list may be possible, and LGC is not responsible for any consequences as a result of these errors, may it be errors in the original Pharmacopoeia data, or from LGC during compilation of this list. For any questions or orders please contact your local LGC office. You will find all contact details on the last page of this list. Alternatively, you can browse and buy pharmaceutical reference materials online at www.lgcstandards.com. Stay connected via LinkedIn (LGC Standards Pharma) or Twitter @LGCStdsPharma Kind regards Your LGC Standards Team LGC, Queens Road, Teddington, Middlesex, TW11 0LY, United Kingdom Tel.: +44 (0)20 8943 8480, Fax: +44 (0)20 8943 7554 E-Mail: [email protected] European Pharmacopoeia (EP) Available Current Unit Cat. No. Name What is new? since Batch No. Quantity 22.12.2016 EPY0001916 Teriparatide 1 1 mg New compound! EPY0001561
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,414.914 B2 Bromley Et Al
    USOO841.4914B2 (12) United States Patent (10) Patent No.: US 8,414.914 B2 Bromley et al. (45) Date of Patent: *Apr. 9, 2013 (54) COMPOSITIONS FOR MIUCOSAL DELVERY (56) References Cited OFAGENTS U.S. PATENT DOCUMENTS (75) Inventors: Philip James Bromley, Fullerton, CA 4,740,365 A 4, 1988 Yukimatsu et al. ........... 424/435 (US); Lee Nickols Huang, Diamond 4,889,720 A 12, 1989 Konishi et al. ......... ... 424/447 4,900,552 A 2f1990 Sanvordeker et all ... 424/422 Bar, CA (US) 4,921,706 A 5/1990 Roberts et al. ..... ... 424/450 5,033,252 A 7/1991 Carter ............................. 534/25 (73) Assignee: Virun, Inc., Walnut, CA (US) 5,052,558 A 10, 1991 Carter ..... ... 206,439 5,154,924 A 10, 1992 Friden ............ 424,179.1 (*) Notice: Subject to any disclaimer, the term of this 5,178,878 A 1/1993 Wehling et al. ............... 424/466 5, 182,107 A 1/1993 Friden ........................ 424,85.91 patent is extended or adjusted under 35 5,234,957 A 8, 1993 Mantelle et al. U.S.C. 154(b) by 0 days. 5,298,246 A 3, 1994 Yano et al. 5,323,907 A 6/1994 Kalvelage ..................... 206,531 This patent is Subject to a terminal dis 5,527,527 A 6/1996 Friden ..... ... 424,178.1 claimer. (Continued) (21) Appl. No.: 13/507,928 FOREIGN PATENT DOCUMENTS CA 2229286 8, 1999 (22) Filed: Aug. 6, 2012 WO WO 2006/0098.25 1, 2006 (65) Prior Publication Data (Continued) US 2012/03O8644 A1 Dec. 6, 2012 OTHER PUBLICATIONS U.S.
    [Show full text]